The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Tue, 30th Jun 2020 21:48

(Adds further details on case, background on investigation)

By Nate Raymond

June 30 (Reuters) - Shaun Thaxter, the former chief
executive of drugmaker Indivior Plc, pleaded guilty on
Tuesday to a criminal charge arising out of a U.S. Justice
Department investigation into the marketing of its opioid
addiction treatment Suboxone.

Thaxter pleaded guilty in federal court in Abingdon,
Virginia to a single misdemeanor count of introducing misbranded
drugs into interstate commerce. The plea came a day after the
company said he was stepping down as CEO.

Prosecutors said Thaxter failed to prevent employees from
sharing false and misleading safety information about the drug
with Massachusetts' Medicaid program as it considered expanding
coverage for it.

Thaxter faces up to one year in prison when he is sentenced
on Sept. 29 and has agreed to pay $600,000 in fines and
forfeitures, the Justice Department said. His attorney did not
respond to requests for comment.

The plea came after Indivior in April 2019 was indicted and
charged with engaging in an illegal scheme to boost
prescriptions of Suboxone in one of the few corporate
prosecutions related to the U.S. opioid addiction
epidemic.

Prosecutors alleged Indivior deceived doctors and healthcare
benefit programs into believing the film version of Suboxone,
which has an opioid component, was safer and less susceptible to
abuse than similar drugs.

The indictment said Indivior also used an internet and
telephone program touted as a resource for opioid addicts to
connect them to doctors it knew were prescribing Suboxone and
other opioids at high rates and in suspect circumstances.

Prosecutors said the scheme began before British consumer
goods company Reckitt Benckiser spun off Indivior.
Reckitt Benckiser in July 2019 agreed to pay $1.4 billion to
resolved related claims.

Slough, England-based Indivior has called the indictment
"wholly unsupported by either the facts or the law." It is
scheduled to face trial in September.
(Reporting by Nate Raymond in Boston
Editing by Chris Reese and Marguerita Choy)

More News
29 Jun 2020 09:29

UK BROKER RATINGS SUMMARY: Jefferies Cuts Balfour Beatty To Hold

UK BROKER RATINGS SUMMARY: Jefferies Cuts Balfour Beatty To Hold

Read more
29 Jun 2020 07:29

Indivior appoints Mark Crossley as CEO after Shaun Thaxter steps down

LONDON, June 29 (Reuters) - British drugmaker Indivior said on Monday it had appointed Mark Crossley as chief executive to replace Shaun Thaxter, who had stepped down in mutual agreement with the board.Crossley has been chief financial officer of ...

Read more
26 Jun 2020 09:37

UPDATE 2-FTSE 100 gains on defensive rally, ends week lower on virus worries

(For a live blog on European stocks, type LIVE/ in an Eikon news window)* BAT, Unilever, Tesco biggest boost to FTSE 100* Pound slides on EU trade deal doubts* Aston Martin slumps on weak outlook, stock offering* FTSE 100 up 0.2%, FTSE 250 up 0.01% ...

Read more
26 Jun 2020 09:21

UK BROKER RATINGS SUMMARY: JPMorgan Raises Rentokil Initial And Bunzl

UK BROKER RATINGS SUMMARY: JPMorgan Raises Rentokil Initial And Bunzl

Read more
23 Jun 2020 13:27

Tuesday broker round-up

(Sharecast News) - Scapa Group: Berenberg reiterates buy with a target price of 150p.

Read more
23 Jun 2020 09:27

UK BROKER RATINGS SUMMARY: Berenberg Likes Direct Line And Hastings

UK BROKER RATINGS SUMMARY: Berenberg Likes Direct Line And Hastings

Read more
16 Jun 2020 09:33

UK BROKER RATINGS SUMMARY: Berenberg Cuts Big Yellow To Hold From Buy

UK BROKER RATINGS SUMMARY: Berenberg Cuts Big Yellow To Hold From Buy

Read more
4 Jun 2020 09:33

UK BROKER RATINGS SUMMARY: Morgan Stanley Upgrades Smith & Nephew

UK BROKER RATINGS SUMMARY: Morgan Stanley Upgrades Smith & Nephew

Read more
3 Jun 2020 16:37

UPDATE 1-UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

(Adds interview with researcher)LONDON, June 3 (Reuters) - British doctors are trialling a formulation of anti-inflammatory ibuprofen to see if it reduces respiratory failure in patients with severe symptoms of COVID-19.The trial involves a partic...

Read more
3 Jun 2020 10:54

UK doctors to trial ibuprofen in COVID-19 patients with breathing difficulties

LONDON, June 3 (Reuters) - British doctors are trialling a formulation of anti-inflammatory ibuprofen to see if it reduces respiratory failure in patients with severe symptoms of COVID-19.The trial involves a particular formulation of ibuprofen, ...

Read more
29 May 2020 09:31

UK BROKER RATINGS SUMMARY: Barclays Lowers Admiral, Raises Direct Line

UK BROKER RATINGS SUMMARY: Barclays Lowers Admiral, Raises Direct Line

Read more
12 May 2020 18:22

Reckitt Benckiser Non-Executive Director Steps Down After Ten Years

Reckitt Benckiser Non-Executive Director Steps Down After Ten Years

Read more
12 May 2020 06:57

Moody's Assigns A3 To New Reckitt Benckiser Notes, Outlook Negative

Moody's Assigns A3 To New Reckitt Benckiser Notes, Outlook Negative

Read more
5 May 2020 15:56

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
4 May 2020 13:34

Monday broker round-up

(Sharecast News) - Go-Ahead Group: Canaccord upgrades to buy with a target price of 1,650p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.